 SAN DIEGO, April 10, 2021 PRNewswire -- Mirati Therapeutics, Inc. NASDAQ: MRTX, a late-stage targeted oncology company, today announced initial preclinical results evaluating its investigational synthetic lethal PRMT5 inhibitor in methylthioadenosine phosphorylase MTAP-deleted cancer models. Miratis internally discovered PRMT5 compound is the first to specifically target the PRMT5methylthioadenosine MTA complex. 